How will the new IMWG definition of active multiple myeloma impact clinical practice?

FAQ Library published on August 18, 2016
Download Transcript Download Audio
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Hi and welcome to Managing Myeloma. My name is Dr. Sagar Lonial, and I am a Professor at the Winship Cancer Institute of Emory University in Atlanta, Georgia. I am frequently asked how the new IMWG definition of active myeloma will impact clinical practice.

I think it has had an immediate impact on clinical practice, because there are a number of patients that now fit the definition of symptomatic myeloma that previously many of us practitioners were very uncomfortable with observing. These are patients with very high levels of free-light chain abnormality and patients who may have normal skeletal surveys but had bone abnormalities by MRI or CT scans, or patients that simply had very high levels of disease burden as evidenced by greater than 60% plasma cells in the bone marrow. What the new criteria allow us to do is to initiate treatment on these patients who clearly have a high risk of progression in a very short time and prevent the development of significant comorbidities such as fractures, anemia, thrombocytopenia, infections, or the incidence of renal failure. So, I think these guidelines are really quite important and help us as practitioners take better care of our patients. Thank you and please tune into ManagingMyeloma.com for additional frequently asked questions.

Last modified: August 10, 2016
Related Items by Author
Practice-changing trials to watch for in 2018
Sagar Lonial, MD, FACP
FAQ Library published on January 24, 2018
A key educational message from ASH 2017
Sagar Lonial, MD, FACP
FAQ Library published on January 12, 2018
Is there a role for Bcl-2 directed treatment for patients with translocation 11;14?
Sagar Lonial, MD, FACP
FAQ Library published on October 11, 2017
How do we determine which patients will benefit the most from treatment with daratumumab and elotuzumab?
Sagar Lonial, MD, FACP
FAQ Library published on July 18, 2016
What is the role of SPEP, UPEP and immunofixation in managing multiple myeloma patients?
Sagar Lonial, MD, FACP
FAQ Library published on July 6, 2016
Is BD or KD a standard of care in relapsed/refractory multiple myeloma?
Sagar Lonial, MD, FACP
FAQ Library published on June 15, 2016
Which is the best indicator of improved outcomes in multiple myeloma: sCR, CR, IFCR or MCR?
Sagar Lonial, MD, FACP
FAQ Library published on May 10, 2016
What new classes of therapy are emerging for multiple myeloma?
Sagar Lonial, MD, FACP
FAQ Library published on March 10, 2016
How does one define high-risk smoldering or asymptomatic multiple myeloma?
Sagar Lonial, MD, FACP
FAQ Library published on November 6, 2014
What are the mechanisms of renal complications in patients with multiple myeloma?
Sagar Lonial, MD, FACP
FAQ Library published on March 15, 2011 in Comorbidities/SEs